HBOT for Migraine and Cluster Headache: What the Evidence Shows

The short answer: For an acute migraine attack, the Cochrane review found HBOT more effective than sham at ending the headache (RR 6.21, 95% CI 2.41–16.00), though from only 58 participants across 3 small trials, rated low quality. HBOT showed no effect on preventing future migraines. Cluster headache is a separate story: there the guideline treatment is normobaric oxygen through a mask at ordinary pressure, not a chamber.

Headache is one of the few areas where oxygen has a genuine, long-standing clinical track record, and also one where two very similar-sounding therapies get confused constantly. Both involve breathing high concentrations of oxygen. Only one of them involves a pressurized chamber, and the research treats them as different interventions with different evidence behind them.

That distinction matters more here than in almost any other topic we cover, because migraine and cluster headache are different disorders that happen to sit next to each other in search results. The oxygen answer for one is not the oxygen answer for the other. This guide separates them, reports what the trials actually measured, and is explicit about where the evidence is thin.

Disclosure: Superhuman Chambers manufactures and sells hyperbaric chambers for wellness operators and home use. This article summarizes published research and is not medical advice. HBOT is not FDA-cleared for migraine, cluster headache, or any headache disorder, and those uses are off-label. Severe, sudden, or changing headaches require evaluation by a physician, not self-treatment.

Normobaric and hyperbaric oxygen are two different treatments

The single most useful thing to understand about oxygen and headache is that “oxygen therapy” describes two distinct interventions that the research keeps carefully apart.

Normobaric oxygen therapy (NBOT) delivers close to 100% oxygen at ordinary atmospheric pressure, through a mask, with no chamber involved. The patient sits up, puts on a non-rebreather mask connected to a cylinder or concentrator, and breathes. Hyperbaric oxygen therapy (HBOT) delivers oxygen inside a sealed chamber pressurized above one atmosphere, which forces substantially more oxygen into blood plasma than a mask can achieve at sea level.

The Cochrane review that anchors this field, Bennett and colleagues (2015), evaluated both and reported them as separate comparisons across 11 trials and 209 participants. Reading its results without tracking which arm is which produces exactly the mix-up that dominates this topic: people conclude that because oxygen helps cluster headache, a hyperbaric chamber must help cluster headache. The trials do not support that step, and the rest of this guide follows the evidence one disorder at a time.

What the evidence shows for HBOT and acute migraine

HBOT has a measurable but preliminary signal for ending a migraine attack in progress, resting on a small number of participants.

Cochrane pooled three randomized trials comparing HBOT against a sham chamber exposure for an active migraine and found a relative risk of 6.21 (95% CI 2.41–16.00) for headache relief. That is a large effect. The confidence interval is also very wide, which is what happens when a pooled result rests on 58 participants in total. The reviewers assigned the finding a GRADE rating of low quality, downgraded for small crossover studies with incomplete reporting.

The trials that produced this result used real hyperbaric pressure. The protocols ran at 2.0 to 2.4 ATA for 40 to 45 minutes, delivered as a single session at the time of the attack rather than as a course of treatment. Myers and Myers (1995) is the most frequently cited of them and used 2.0 ATA, comparing it against a low-pressure sham.

The prevention result deserves emphasis because it is where marketing most often outruns the data. Cochrane states plainly that it found no evidence that HBOT could prevent migraine episodes, and its practice implication is that prophylactic use “is not supported by the evidence.” A single 2019 case report describes one patient improving over 40 sessions at 1.5 ATA, but a single uncontrolled patient is a hypothesis, not a finding.

The field has been quiet since 2015

No randomized trial, systematic review, or meta-analysis of HBOT for migraine has been published since the Cochrane review, and ClinicalTrials.gov currently lists no registered HBOT trial for migraine or cluster headache. The honest description is not that HBOT for migraine has been disproven. It is that a promising early signal was never followed up, and the question has sat unanswered for a decade.

Cluster headache: why the guidelines point to a mask

For cluster headache, every major neurology guideline recommends high-flow oxygen delivered at ordinary pressure, and none recommends a chamber.

Cluster headache attacks peak within roughly 5 to 10 minutes and can recur several times a day, which places an unforgiving constraint on any treatment: it has to be available immediately, wherever the patient is. Mask oxygen meets that constraint. The American Headache Society’s 2016 guideline gives high-flow oxygen a Level A recommendation for acute treatment alongside subcutaneous sumatriptan and zolmitriptan nasal spray, specifying 100% oxygen at 6 to 12 L/min. The American Academy of Neurology reached the same Level A conclusion.

The evidence underneath that recommendation is solid for a headache intervention. Cohen, Burns, and Goadsby (2009) ran a double-blind randomized crossover trial in JAMA with 109 patients randomized and 76 analyzed, treating each patient’s attacks with either 100% oxygen at 12 L/min by face mask for 15 minutes or high-flow air. 78% of oxygen-treated attacks (95% CI 71–85%) were pain-free at 15 minutes versus 20% of air-treated attacks (95% CI 14–26%), P<0.001.

Delivery details decide whether this works. The European Academy of Neurology’s 2023 guideline specifies at least 12 L/min of 100% oxygen, in some cases up to 15 L/min, for 20 minutes using a non-rebreather mask, and states directly that nasal cannulae are not sufficient. A cannula cannot deliver the required concentration, which is a common and consequential mistake.

Cochrane’s own read on HBOT for this disorder is that the evidence is not there rather than that the therapy failed. One small trial produced a relative risk of 11.38 with a confidence interval running from 0.77 to 167.85 (P=0.08), an interval so wide it establishes nothing in either direction, and the reviewers concluded there is insufficient evidence from good-quality trials to determine whether HBOT helps cluster headache at all.

How oxygen is thought to work, and what is still unknown

The mechanism behind oxygen’s effect on headache remains genuinely unsettled, and the most-repeated explanation is the weakest one.

The popular account is that oxygen constricts cerebral blood vessels and that this ends the headache. The vasoconstriction itself is real and well documented: breathing 100% oxygen reduces cerebral blood flow by roughly 9% to 31%. Whether that is what stops the pain is much less clear, and a 2023 randomized double-blind study concluded that the mechanism of action is still unknown.

The better-supported mechanisms are neural rather than vascular. Akerman and colleagues (2009) showed in rats that 100% oxygen inhibits neuronal firing in the trigeminocervical complex after stimulation of the trigeminal autonomic reflex, by a maximum of 33% at 20 minutes. Notably, oxygen did not inhibit firing evoked directly at the dura, which argues against the simple vasoconstriction story. On the human side, Goadsby and Edvinsson (1994) sampled jugular blood during spontaneous cluster attacks and found elevated CGRP normalizing as oxygen ended the attack, an association rather than a demonstrated cause.

One mechanism worth explicitly setting aside: the claim that oxygen suppresses cortical spreading depression, the wave associated with migraine aura, has no supporting primary study and has been directly tested and contradicted. Anyone citing it is repeating an error.

The pressure question that decides equipment

The migraine trials ran at 2.0 to 2.4 ATA, which is well above what mild soft-shell chambers reach, and this is the detail that determines whether a given chamber is relevant at all.

This point gets skipped almost everywhere, so it is worth stating in numbers. The positive acute-migraine result came from sessions at 2.0 ATA and above on 100% oxygen. Mild or soft-shell chambers, the category most often sold for home use, typically operate at 1.3 to 1.5 ATA, and many are run on concentrator air rather than near-100% oxygen. That is not a small difference in degree. It is a different exposure from the one the trials tested, and no study has established that the lower exposure reproduces the result.

The practical reading is straightforward. If hyperbaric oxygen is being considered for migraine specifically, the relevant hardware is hard-shell equipment capable of a true 2.0 ATA under medical supervision, such as our Superhuman L1, rather than a mild home unit. A soft-shell chamber like the S1 is a legitimate product for general wellness use at 1.3 to 1.5 ATA, but it does not reach the pressures in this literature, and we would rather say so than let the distinction blur. Buyers weighing that trade-off can compare chambers from $15,000 across both pressure tiers before deciding. Our explainer on hyperbaric chamber pressure levels covers the 1.3 versus 1.5 versus 2.0 ATA difference in detail.

Cleared, approved, and covered

Neither migraine nor cluster headache appears on any list of approved hyperbaric indications, and being clear about that is part of using the therapy responsibly.

• FDA-cleared: no. The FDA has cleared hyperbaric chambers for a specific set of conditions, and headache disorders are not among them. In its 2013 consumer guidance the agency named migraine explicitly as a condition for which hyperbaric chambers had not been cleared or approved.
• UHMS-approved: no. The Undersea and Hyperbaric Medical Society’s list of approved indications contains no headache disorder of any kind.
• Insurance-covered: generally no, for the chamber. Medicare’s national coverage determination for HBOT does not list headache. For normobaric home oxygen in cluster headache the picture changed in September 2021, when CMS removed its national non-coverage decision and left the question to regional contractors, so coverage now varies by region rather than being categorically refused.

Access remains the real-world obstacle for cluster headache patients even though mask oxygen is guideline-endorsed. A joint statement from the American Headache Society and the American Migraine Foundation reported that while 74% of surveyed patients who tried oxygen found it effective or very effective, 41% who were prescribed home oxygen were denied by their insurer. A separate survey of 2,193 patients found oxygen completely or very effective for 54%, with minimal adverse effects.

Limitations and open questions

The boundaries around this evidence are wide enough that they belong in any honest summary.

• The migraine result rests on 58 people. Three small crossover trials, rated low quality by the reviewers, are a starting point rather than an established treatment effect.
• Nothing new has been published since 2015. A decade without a follow-up trial means the question is open, not settled, in either direction.
• Prevention is not supported. Cochrane found no effect on preventing migraine episodes, and claims that HBOT reduces attack frequency are not backed by the pooled evidence.
• HBOT for cluster headache is unestablished. One underpowered trial with a confidence interval spanning 0.77 to 167.85 cannot support a recommendation.
• The studied pressures were 2.0 ATA and above. Mild-pressure chambers are untested for this use.
• Hyperbaric exposure can itself cause headache. A review of 4,245 chamber sessions notes that some participants experienced headache during treatment, alongside the more familiar risk of middle-ear barotrauma.
• The mechanism is unresolved. Researchers testing it directly concluded in 2023 that it remains unknown.

What this means for wellness operators

The responsible position is to treat headache as a referral conversation and to be precise about which oxygen therapy is under discussion.

First, know which disorder is in front of you. Cluster headache has a Level A guideline treatment that involves a mask and a flow rate, not a chamber, and a person describing severe one-sided attacks with tearing and nasal congestion needs a neurologist rather than a session booking. Recognizing that and referring appropriately builds far more credibility than accommodating the request.

Second, match the claim to the pressure. The only positive hyperbaric headache signal came from 2.0 ATA and above, in acute migraine, from a small and dated evidence base. An operator running mild soft-shell equipment cannot support a migraine claim with that hardware, and an operator running hard-shell equipment still cannot present a low-quality result as an established one. Our guides to hard-shell versus soft-shell chambers and HBOT side effects and contraindications cover the equipment and screening side.

Third, screen before pressurizing anyone. Barotrauma risk, ear and sinus clearance, and the standard hyperbaric contraindications apply regardless of the reason for the session, and headache patients are not exempt. To talk through how an evidence-first hyperbaric program should be positioned, you can learn more about Superhuman or contact the team.

References

1. Bennett MH, French C, Schnabel A, Wasiak J, Kranke P, Weibel S. Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache. Cochrane Database Syst Rev. 2015;2015(12):CD005219. PMID 26709672.
2. Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA. 2009;302(22):2451–2457. PMID 19996400.
3. Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016;56(7):1093–1106. PMID 27432623.
4. Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology. 2010;75(5):463–473. PMID 20679639.
5. May A, Evers S, Goadsby PJ, et al. European Academy of Neurology guidelines on the treatment of cluster headache. Eur J Neurol. 2023;30(10):2955–2979. PMID 37515405.
6. Myers DE, Myers RA. A preliminary report on hyperbaric oxygen in the relief of migraine headache. Headache. 1995;35(4):197–199. PMID 7775175.
7. Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of trigeminal autonomic reflex, but not during direct dural activation of trigeminal afferents. Headache. 2009;49(8):1131–1143. PMID 19719541.
8. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain. 1994;117(Pt 3):427–434. PMID 7518321.
9. Schröder CF, Basedau H, Moeller M, May A. Oxygen inhalation has no effect on provoked cranial autonomic symptoms using kinetic oscillation stimulation in healthy volunteers. Cephalalgia. 2023;43(4):3331024231161269. PMID 36918826.
10. Pearson SM, Burish MJ, Shapiro RE, Yan Y, Schor LI. Effectiveness of Oxygen and Other Acute Treatments for Cluster Headache. Headache. 2019;59(2):235–249. PMID 30632614.
11. Churchill S, Deru K, Weaver LK, Wilson SH, Hebert D, Miller RS. Adverse events and blinding in two randomized trials of hyperbaric oxygen for persistent post-concussive symptoms. Undersea Hyperb Med. 2019;46(3):331–340. PMID 31394602.
12. Matera DV, Smith B, Lam B. Revisiting the expanded use of hyperbaric oxygen therapy for treatment of resistant migraines. Med Gas Res. 2019;9(4):238–240. PMID 31898611.